SCLX · Scilex Holding Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.61M | - | $10.56M | $9.90M | $5.00M | - | $14.44M | $16.37M | $10.88M | - |
| Cost of Revenue | $4.45M | - | $3.33M | $3.27M | $1.38M | - | $3.77M | $4.39M | $3.84M | - |
| Gross Profit | $17.70M | - | $7.23M | $6.62M | $3.62M | - | $10.67M | $11.98M | $7.04M | - |
| R&D | $3.21M | - | $3.90M | $6.19M | $2.46M | - | $2.35M | $2.00M | $3.11M | - |
| SG&A | $31.03M | - | $188.82M | $19.84M | $28.06M | - | $29.73M | $24.60M | $29.28M | - |
| Total Operating Expenses | $40.78M | - | $197.07M | $30.40M | $32.90M | - | $34.35M | $31.99M | $30.36M | - |
| D&A | $2.87M | - | $2.0K | $2.0K | $1.00M | - | $4.0K | $4.0K | $1.03M | - |
| Operating Income | ($32.17M) | - | ($186.51M) | ($20.51M) | ($27.90M) | - | ($19.92M) | ($15.62M) | ($19.48M) | - |
| Interest Expense | $3.78M | - | $2.80M | $571.0K | $531.0K | - | $576.0K | $5.0K | $531.0K | - |
| Income Tax | - | - | $1.0K | $19.0K | - | - | $0 | $0 | $0 | - |
| Net Income | ($45.65M) | - | ($257.82M) | ($44.05M) | ($26.08M) | - | ($4.39M) | ($37.58M) | ($24.38M) | - |
| EPS - Basic | ($6.28) | - | ($22.17) | ($7.42) | ($2.26) | - | ($1.05) | ($10.85) | ($8.40) | - |
| EPS - Diluted | ($6.28) | - | ($22.17) | ($7.42) | ($2.26) | - | ($1.05) | ($10.85) | ($8.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.35M | $4.96M | $878.0K | $4.10M | $5.80M | $3.27M | $77.0K | $6.89M | $1.82M | $3.92M |
| Accounts Receivable | $10.65M | $15.24M | $11.94M | $16.77M | $10.62M | $26.44M | $31.58M | $38.00M | $29.72M | $34.60M |
| Inventory | $4.53M | $4.79M | $1.08M | $2.52M | $3.02M | $2.44M | $2.40M | $3.07M | $3.49M | $4.21M |
| Accounts Payable | $101.58M | $86.27M | $67.36M | $59.16M | $57.26M | $52.62M | $43.40M | $41.79M | $42.22M | $40.95M |
| Current Assets | $41.97M | $38.36M | $16.49M | $33.67M | $28.70M | $41.55M | $39.85M | $50.42M | $37.74M | $46.78M |
| Total Assets | $293.63M | $364.98M | $275.88M | $83.75M | $78.98M | $92.95M | $100.43M | $104.54M | $91.24M | $101.31M |
| Current Liabilities | $501.75M | $483.65M | $358.95M | $305.93M | $275.74M | $259.63M | $281.54M | $255.45M | $252.73M | $250.38M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $547.71M | $576.73M | $455.60M | $332.74M | $290.46M | $285.59M | $311.75M | $319.24M | $281.03M | $274.25M |
| Stockholders' Equity | ($249.22M) | ($207.78M) | ($176.94M) | ($248.99M) | ($211.48M) | ($192.64M) | ($211.32M) | ($214.69M) | ($189.79M) | ($172.94M) |
| Retained Earnings | ($965.06M) | ($921.79M) | ($888.67M) | ($631.44M) | ($589.13M) | ($563.05M) | ($556.59M) | ($552.20M) | ($514.62M) | ($490.25M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.11M) | - | - | - | $6.01M | - | - | - | $9.39M | - |
| Investing Cash Flow | ($9.16M) | - | - | - | ($395.0K) | - | - | - | ($150.0K) | - |
| Financing Cash Flow | $9.14M | - | - | - | ($3.08M) | - | - | - | ($11.20M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 205.5% | - | 68.5% | 66.9% | 72.3% | - | 73.9% | 73.2% | 64.7% | - |
| Operating margin | -373.5% | - | -1766.2% | -207.2% | -557.5% | - | -138.0% | -95.4% | -179.0% | - |
| EBITDA margin | -340.2% | - | -1766.2% | -207.2% | -537.5% | - | -137.9% | -95.4% | -169.5% | - |
| Net margin | -530.0% | - | -2441.5% | -445.1% | -521.2% | - | -30.4% | -229.6% | -224.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 37.3% | - | 36.9% | 62.5% | 49.1% | - | 16.3% | 12.2% | 28.6% | - |
| SG&A / Revenue | 360.3% | - | 1788.1% | 200.5% | 560.8% | - | 206.0% | 150.3% | 269.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -15.5% | - | -93.5% | -52.6% | -33.0% | - | -4.4% | -35.9% | -26.7% | - |
| Return on equity | 18.3% | - | 145.7% | 17.7% | 12.3% | - | 2.1% | 17.5% | 12.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.08 | 0.08 | 0.05 | 0.11 | 0.10 | 0.16 | 0.14 | 0.20 | 0.15 | 0.19 |
| Quick ratio | 0.07 | 0.07 | 0.04 | 0.10 | 0.09 | 0.15 | 0.13 | 0.19 | 0.14 | 0.17 |
| Cash ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.03 | 0.01 | 0.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -8.5x | - | -66.7x | -35.9x | -52.5x | - | -34.6x | -3124.6x | -36.7x | - |
| Equity multiplier | -1.18 | -1.76 | -1.56 | -0.34 | -0.37 | -0.48 | -0.48 | -0.49 | -0.48 | -0.59 |
| Liabilities / Assets | 1.87 | 1.58 | 1.65 | 3.97 | 3.68 | 3.07 | 3.10 | 3.05 | 3.08 | 2.71 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.04 | 0.12 | 0.06 | - | 0.14 | 0.16 | 0.12 | - |
| Inventory turnover | 0.98 | - | 3.08 | 1.30 | 0.46 | - | 1.57 | 1.43 | 1.10 | - |
| Days sales outstanding | 451d | - | 413d | 618d | 775d | - | 798d | 847d | 997d | - |
| Days inventory outstanding | 372d | - | 119d | 281d | 796d | - | 233d | 255d | 331d | - |
| Days payable outstanding | 8337d | - | 7386d | 6599d | 15100d | - | 4204d | 3474d | 4013d | - |
| Cash conversion cycle | -7514d | - | -6854d | -5699d | -13530d | - | -3173d | -2371d | -2685d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 5.3x | - | 0.0x | 0.0x | 0.0x | - | 0.3x | 0.5x | 0.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 72.1% | - | -26.8% | -39.5% | -54.0% | - | 26.9% | 106.5% | 2.9% | - |
| Revenue CAGR (3y) | -6.6% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 389.0% | - | -32.2% | -44.7% | -48.6% | - | 33.6% | 87.3% | -25.4% | - |
| Operating income growth (YoY) | -15.3% | - | -836.4% | -31.3% | -43.2% | - | 48.7% | 31.5% | 23.5% | - |
| Net income growth (YoY) | -75.0% | - | -5775.6% | -17.2% | -7.0% | - | 87.6% | -41.0% | 20.7% | - |
| EPS growth (YoY) | -177.9% | - | -2011.4% | 31.6% | 73.1% | - | -66.7% | -5610.5% | -3718.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -17.8% | -7.9% | 16.3% | -16.0% | -11.4% | -11.4% | -29.9% | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Scilex Holding Co against the 5 most active filers in the same SIC group.